ReviewEuropean heart journal. Cardiovascular pharmacotherapy2024

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.

Shaun G Goodman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.